匹多莫德口服液联合蒲地兰消炎口服液治疗儿童手足口病的临床研究

目的探究匹多莫德口服液联合蒲地兰消炎口服液治疗儿童手足口病的临床疗效。方法选取2014年5月—2016年5月在首都医科大学附属北京同仁医院治疗的手足口病儿童患者84例,随机分为对照组和治疗组,每组各42例。对照组患儿口服蒲地兰消炎口服液,1岁以下5 m L/次,1~3岁6.7 m L/次,3岁以上10 m L/次,3次/d。治疗组患儿在对照组的基础上口服匹多莫德口服液,400 mg/次,2次/d。两组患儿均连续治疗6 d。比较两组患儿临床疗效、总病程时间、体征平均消失时间及治疗前后血常规和血清C反应蛋白(CRP)变化。结果治疗后,对照组和治疗组的总有效率分别为88.10%、97.62%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,治疗组患者的总病程时间和各种病症消失时间均显著短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者白细胞(WBC)、中性粒细胞(GRAN)、肌酸激酶(CK)和CRP水平均显著接近正常值,同组比较差异具有统计学意义(P0.05);且治疗后治疗组患者血常规和血清CRP改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。结论匹多莫德口服液联合蒲地兰消炎口服液对儿童手足口病具有更高的有效率和改善效果,具有一定的临床推广应用价值。

Clinical study on Pidotimod Oral Solution combined with Pudilan Antiphlogistic Oral Liquid in treatment of children with hand-foot-and-mouth disease

Objective To explore the clinical value of Pidotimod Oral Solution combined with Pudilan Antiphlogistic Oral Liquid in treatment of children with hand-foot-and-mouth disease. Method Children (84 cases) with hand-foot-and-mouth disease in Beijing Tongren Hospital, CMU from May 2014 to May 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Children in the control group were po administered with Pudilan Antiphlogistic Oral Liquid, 5 mL/time for under 1 year old children, 6.7 mL/time for 1-3 years old children, and 10 mL/time for over 3 years old children, three times daily. Children in the treatment group were po administered with Pidotimod Oral Solution on the basis of the control group, 400 mg/time, twice daily. Children in two groups were treated for 6 d. After treatment, the clinical efficacy, total disease course, average disappearance time of symptoms, and change of blood routine and serum CRP in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.10% and 97.62%, respectively, and there was difference between two groups (P<0.05). After treatment, the total disease course and the average disappearance time of symptoms in the treatment were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, WBC, GRAN, CK, and CRP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood routine and serum CRP in the treatment were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pidotimod Oral Solution combined with Pudilan Antiphlogistic Oral Liquid has a higher efficiency and improved effect in treatment of children with hand-foot-and-mouth disease, which has a certain clinical application value.